Norbel Baby Co. Ltd., a Qisda Corporation subsidiary specializing in pharmacy retail, has released its 2023 financial report, posting a net profit of NT$110 million, representing a 46.3% year-over-year decline. The company reported an earnings per share (EPS) of NT$3, with its board approving a cash dividend of NT$2.6 per share, supplemented by an additional NT$2.5 per share from capital reserves, bringing the total payout to NT$5.1 per share. Based on the closing price of NT$137.5 on March 4, this translates to a cash dividend yield of 3.7%.
Despite a decline in full-year profits, Norbel Baby Co. Ltd. reported January revenue of NT$311 million, marking an 11.36% year-over-year increase and the highest monthly sales in 18 months. The surge was attributed to robust consumer demand during the Lunar New Year holiday, as stores remained open, driving strong sales in nutritional supplements, personal care products, and baby essentials.
Norbel Babys Ding Ding Pharmacy(丁丁藥局), originally known for maternal and infant products, has strategically expanded into elder care, long-term care, and home medical equipment to cater to Taiwan’s rapidly aging population. The company is actively pursuing a dual-growth strategy, combining store expansion with strategic investments to solidify its market leadership. By the end of 2024, Ding Ding Pharmacy had officially surpassed 100 store locations, with further expansion planned for 2025.
Following its acquisition by Qisda in Q4 2024, Norbel Baby Co. Ltd. has become a key pillar in Qisda’s pharmacy retail and healthcare distribution strategy. Qisda Chairman Peter Chen has emphasized healthcare as a high-value transformation focus for the company, integrating BenQ Hospital as a flagship medical provider alongside growth in medical devices and pharmaceutical distribution. With the global shift toward aging societies, Qisda aims to deliver comprehensive healthcare solutions that enhance healthy aging and quality of life.
Resource: 諾貝兒去年EPS 3元 發放股利加資本公積共5.1元
